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REVIEW
Abstract: Angiotensin-converting enzyme (ACE) inhibitors effectively interfere with the
renin–angiotensin system and exert various beneficial actions on vascular structure and function
beyond their blood pressure-lowering effects. Zofenopril, a potent sulphydryl ACE inhibitor,
is characterized by high lipophilicity, sustained cardiac ACE inhibition, and antioxidant and
tissue protective activities. Its ancillary properties, such as antioxidant activity and
cardiovascular (CV) protection, make this drug potentially suitable for the treatment and
prevention of certain CV diseases. The Survival of Myocardial Infarction Long term Evaluation
trials have demonstrated that the early administration of zofenopril to patients with acute
myocardial infarction is associated with a significant reduction in the 6-week occurrence of
major CV events in high-risk patients with anterior non-thrombolyzed myocardial infarction.
The fixed combination of zofenopril–hydrochlorothiazide (HCTZ) 30/12.5 mg/day is approved
for the management of mild-to-moderate hypertension in different European countries. In
clinical trials comparing zofenopril–HCTZ with each agent administered as monotherapy,
combination therapy was clearly more effective in normalizing blood pressure (BP). In addition,
combination therapy provided sustained and consistent BP control over the entire 24 hour
dosing interval. The efficacy and safety profile of zofenopril–HCTZ highlights that this
combination is a potentially useful addition to currently available therapy for patients with
BP inadequately controlled by monotherapy, as well as for patients who require more rapid
and intensive BP control.
Keywords: zofenopril, hydrochlorothiazide, mild-to-moderate hypertension, combination
therapy
Introduction
Hypertension is the most commonly occurring independent risk factor for
cardiovascular (CV) disease in both developed and developing countries (Ezzati et
al 2002). The life-long prevalence of developing hypertension after the sixth decade
of life is reportedly 90% (Franklin et al 2001). On the other hand, effective treatment
of hypertension is associated with a reduction in adverse CV events (Collins and
MacMahon 1994; Hansson et al 1998). A meta-analysis of data sampled in more
than 47 000 patients showed that a sustained reduction of 5 mmHg to 6 mmHg in
diastolic blood pressure (DBP) resulted in a risk reduction of more than 50% for
heart failure, up to 40% for stroke and 20% to 25% for coronary heart disease (Vasan
et al 2001). Data from the Hypertension Optimal Treatment (HOT) trial, evaluating
approximately 19 000 patients reported that the lowest incidence of major
cardiovascular events occurred at a mean achieved DBP of 82.6 mmHg. In addition,
in a subgroup analysis, a 50% reduction in major CV events was observed in patients
with hypertension and diabetes randomized to a target DBP of ≤80 mmHg (Hansson
et al 1998; WHO–ISH 2003).
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Current guidelines for the management of hypertension
recommend treating all hypertensive patients to target
systolic blood pressure (SBP)/DBP values of ≤140/
90 mmHg, and for patients with hypertension and
comorbidities such as diabetes or renal disease to a target
of <130/80 mmHg (ESH–ESC 2003; JNC-7 2003).
Beyond these recommendations, according to recent US
data (Hajjar and Kotchen 2003), a large proportion of the
hypertensive population (about 50%) are unaware of their
high BP values and, consequently, are not currently treated
for hypertension. Among those who are aware and treated
for hypertension, the actual degree of adequate BP control
is far from satisfactory, and does not attain the 30% level of
treated patients across almost all Western countries (Wang
and Vasan 2005).
Similar results have been provided by an extensive
review of the extent of blood pressure management in
European countries (EUROASPIRE II 2001). Poor BP
control is responsible for a significant increase in the
economic burden of treating hypertension, since it increases
the proportion of patients who do not achieve any clinical
benefit from treatment, despite their involvement in a costly
treatment program. Several different reasons have been
identified to explain the poor extent of BP control, including:
1) inadequate compliance to treatment; 2) insufficient use
of drug combinations; and 3) the high proportion of patients
who withdraw from treatment because of incomplete BP
control (Ambrosioni et al 2000).
The main ways to improve the patient compliance to
antihypertensive treatment appear to be the use of first-line
therapy that are: 1) well tolerated; 2) mono-administered;
3) efficacious (JNC 7 2003).
In this context, angiotensin-converting enzyme (ACE)
inhibitors are one of the most safe and efficacious class of
antihypertensive drugs (Khalil et al 2001).
Rationale for combination therapy
It is now recognized that the majority of patients will require
at least two antihypertensive drugs to achieve optimal BP
control (Hannson et al 1998; Kearney et al 2005). The
European Society of Hypertension – European Society of
Cardiology (ESH–ESC) guidelines recommend the use of
either low-dose monotherapy or low-dose combination
therapy with two agents (eg, a beta-blocker and a diuretic
or an ACE inhibitor and a diuretic) (ESH–ESC 2003). The
Joint National Committee 7 (JNC-7) report states that the
addition of a second agent from a different class should be
initiated when the use of monotherapy fails to achieve
adequate control of BP (JNC-7 2003).
From a prognostic point of view, what appears to be
more relevant in the first choice of an antihypertensive agent
is its efficacy in normalizing BP: the HOT trial demonstrated
that greater BP reductions and higher response rates are
achieved with the use of combination therapy (Hannson et
al 1997, 1998). In this trial, a total of 85% of patients
achieved a DBP of ≤90 mmHg, but only approximately one-
third of patients remained on monotherapy. Interestingly,
27% of patients had well controlled BP when treated
according to step 2 treatment, consisting of a low-dose
combination of two agents.
A lack of patient compliance is not sufficient to
completely account for the poor treatment rates and low
target attainment observed in patients with hypertension
(Wetzels et al 2004). As demonstrated by the HOT trial,
monotherapy simply does not result in BP lowering to or
below target levels in the majority of patients.
Fixed-dose combination therapy is likely to be more
effective in achieving BP goals and result in greater patient
compliance than titrating individual doses of two single
agents (Moser 2003). Furthermore, fixed dose combination
therapy offers beneficial BP lowering effects while
minimizing the adverse effects that are potentially associated
with the titration of each agent administered singly (Mancia
and Grassi 1999; Zanchetti 1999).
An effective fixed-dose two-drug combination should
have: complementary mechanisms of action; an
antihypertensive effect that is at least as, if not more,
effective than either agent administered singly or as
sequential combination therapy; enhanced ability to offer
end-organ protection, and minimal adverse effects
(including, hemodynamic and metabolic effects) (Mancia
and Grassi 1999; Zanchetti 1999).
The investigation of the renin–angiotensin system began
with the discovery of renin in 1898 by Tiegerstedt and
Bergman and was followed by the observation in 1940 that
renin acted on a plasma protein substrate to catalyze the
formation of a pressor peptide, angiotensin (Vane 1999).
This plasma precursor is angiotensinogen and two forms of
angiotensin, angiotensin I and II, were recognized in the
mid 1950s. The conversion of inactive angiotensin I to the
active angiotensin II occurs via ACE (Soubrier et al 1988).
Since these initial discoveries, efforts to manipulate the
renin–angiotensin system have resulted in the synthesis of
the first orally effective ACE inhibitor, captopril. A seriesVascular Health and Risk Management 2006:2(4) 343
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of other ACE inhibitors have now been synthesized
(Cushman et al 1977).
Thiazides are effective and inexpensive antihypertensive
agents, but their use at full doses is associated with various
side effects and low patient compliance (JNC-7 2003).
There are three distinct advantages associated with the
combination of an ACE inhibitor and a diuretic (Mancia et
al 1997; Zanchetti 1999). Firstly, this combination, utilizing
a low-dose diuretic, reduces the probability of adverse
metabolic effects often associated with the use of high-dose
diuretic therapy (JNC-7 2003). ACE inhibitors are also
known to effectively counteract the tendency of thiazide
diuretics to lower serum potassium levels. In addition, HCTZ
may increase oxidant activity via an activation of the renin–
angiotensin system, and zofenopril has a direct antioxidant
effect in humans (Napoli et al 2004).
Secondly, the use of a fixed combination reduces the
number of tablets taken daily, thus improving patient
compliance.
Thirdly, combination therapy may be, at least, as equally
effective as monotherapy in the prevention of organ damage
associated with hypertension. ACE inhibitor therapy in
combination with a diuretic has been shown to be effective
in reducing left ventricular hypertrophy (LVH) (Mancia et
al 1997). In clinical trials in patients with hypertension and
diabetes, an ACE inhibitor in combination with a diuretic
plays a role in retarding the progression of renal failure in
diabetic and other types of nephropathy (Lewis et al 1993;
Giatras et al 1997; Zanchetti and Ruilope 2002).
Clinical efficacy of Zofenopril–
HCTZ
Zofenopril, a new potent sulphydryl ACE inhibitor, is
characterized by high lipophilicity, sustained cardiac ACE
inhibition, antioxidant and tissue protective activities
(Borghi and Ambrosioni 2000; Matarrese et al 2004) (Figure
1).
Hydrochlorothiazide is the 3,4-dihydro-derivative of
chlorothiazide (Figure 1). It affects the renal tubular
mechanisms of electrolyte resorption, directly increasing
excretion of sodium. Indirectly, the diuretic action of HCTZ
reduces plasma volume with consequent increases in plasma
renin activity, aldosterone secretion and urinary potassium
loss, and decreases in serum potassium (Reyes 2002).
The fixed-dose combination of zofenopril–HCTZ 30/
12.5 mg/day is approved for the management of mild-to-
moderate hypertension. In clinical studies this combination
was more effective in maintaining BP reduction than either
agent administered as monotherapy (Malacco and Omboni
2005; Parati et al 2005). This result was particularly evident
in patients who were non-responsive to zofenopril
monotherapy (Malacco and Omboni 2005).
Three pivotal studies have investigated the clinical
efficacy of this combination (Malacco and Omboni 2005;
Parati et al 2005). In all studies a stable baseline elevated
BP was confirmed by repeated measurement of seated or
standing SBP/DBP during a single-blind, placebo run-in
period of 2 to 4 weeks duration. Inclusion criteria for these
studies included a seated DBP of: 95 mmHg to 110 mmHg
for the dose-response study (Parati et al 2005); 95 mmHg
to 115 mmHg for the parallel-group comparative study
(Study 1), and 90 mmHg to 110mmHg for the non-responder
group study (Study 2) (Malacco and Omboni 2005). Patients
eligible for randomization to treatment were required to meet
the criteria for seated DBP at inclusion and also for intra-
and inter-visit variability (<10 mmHg). Randomized,
double-blind treatment was given as a once daily regimen
at the same time each day. BP was measured approximately
24 h after the previous dose by cuff sphygmomanometer
A 
B 
Figure 1 Chemical structure of zofenopril (A) and hydrochlorothiazide (B).Vascular Health and Risk Management 2006:2(4) 344
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and in the dose-response study by ambulatory BP monitoring
(ABPM).
Dose-response study
The results of a 12-week multi-center dose-response study
in 353 patients with essential hypertension demonstrated
that combination therapy with zofenopril–HCTZ (30/
12.5 mg/day or 60/12.5 mg/day) was more effective in
maintaining continuous 24 h BP control than either agent
administered alone (Parati et al 2005).
Patients aged 18 to 75 years were randomized to double-
blind treatment with zofenopril 15 mg, 30 mg or 60 mg,
HCTZ 12.5 mg or 25 mg or their combination for 12 weeks.
The primary efficacy endpoint, proportion of patients
achieving office BP normalization (seated DBP <90 mmHg),
was greater for the combination of zofenopril–HCTZ than
either agent administered as monotherapy and reached
significance at the 30/12.5 mg/day, 60/12.5 mg/day and 30/
25 mg/day doses (p<0.05).
The combination of zofenopril–HCTZ 30/12.5 mg
normalized BP in 57% of patients compared with a
normalization rate of 33% for HCTZ 12.5 mg/day (p<0.05).
A total of 76% of patients administered the 30/12.5 mg
combination exhibited normalized BP or a DBP reduction
≥10 mmHg (responders) in contrast with 42% on HCTZ
12.5 mg/day (p<0.01). Further reductions were observed
with zofenopril–HCTZ 60/12.5 mg/day but not when HCTZ
was increased to 25 mg/day. Similar results were observed
with regard to SBP also, even if this was not a primary goal
of the study.
Both 24 h and hourly changes in BP were greater with
zofenopril–HCTZ 30/12.5 mg/day, 60/12.5 mg/day and 30/
25 mg/day combination treatment than with either agent
administered singly.
Furthermore, higher smoothness indices, evaluated by
ABPM, indicated that combination therapy, in particular 30/
12.5 mg/day and 30/25 mg/day, provided superior BP control
over the dosing interval compared with monotherapy
(Zanchetti et al 2006).
Comparative studies
Two international multi-center, randomized, double-blind,
parallel-group studies have evaluated the combination of
zofenopril–HCTZ 30/12.5 mg/day compared with
monotherapy with zofenopril 30 mg/day (Malacco and
Omboni 2005).
A 36-week comparison of zofenopril–HCTZ and
zofenopril monotherapy demonstrated the superior efficacy
of combination therapy in lowering BP in 463 patients aged
18 to 75 years with mild-to-moderate hypertension.
Following a 4-week washout period, the 12-week efficacy
endpoint of reduction in DBP and SBP, and the proportion
of responders were significantly greater with combination
therapy than zofenopril monotherapy (p<0.001).
A second study of 369 patients, 18 to 70 years of age,
confirmed the efficacy of combination therapy in treating
patients with mild-to-moderate hypertension who were not
responsive to zofenopril monotherapy (Malacco and
Omboni 2005). Following a 4-week placebo run-in phase,
eligible patients were administered 4-weeks’ treatment with
zofenopril 30 mg/day in a single-blind fashion. Non-
responders (SBP ≥130 mmHg and DBP ≥85 mmHg and/or
SBP reduction <20 mmHg and/or DBP reduction
<10 mmHg) were then randomized to double-blind treatment
with zofenopril–HCTZ 30/12.5 mg/day or zofenopril 30 mg/
day for 8 weeks. Significantly greater and more consistent
reductions in BP and higher response rates were reported
with combination therapy than with zofenopril monotherapy.
In those patients receiving zofenopril monotherapy BP
reached a plateau at week 8 but continued to decrease in
patients receiving combination therapy.
Finally, while these results are encouraging, further
clinical data are needed to assess the long-term efficacy of
the zofenopril–HCTZ combination on specific clinical
outcomes
Zofenopril–HCTZ and end-organ
protection
In addition to hypertension and other CV risk factors (ie,
hyperlipidemia, diabetes) it has been recognized that
activation of the renin–angiotensin–aldosterone system
(RAAS) plays a role in the risk of CV disease-related
morbidity and mortality (Toto et al 2004; Dzau 2005).
Angiotensin II has been shown to have a direct effect on
various tissues including endothelial, vascular and renal
tissues (Toto et al 2004).
Pharmacological agents such as ACE inhibitors, that
actively prevent the formation of angiotensin II, may
therefore have a beneficial effect in terms of end-organ
protection beyond their activity on BP. Data from clinical
trials with an ACE inhibitor, such as the Heart Outcomes
Prevention Evaluation (HOPE) study, confirm the efficacy
of these agents in reducing the risk of CV death, myocardial
infarction and stroke (Yusuf et al 2000).
No large randomized clinical trial has yet demonstrated
the long-term efficacy of the zofenopril–HCTZ combinationVascular Health and Risk Management 2006:2(4) 345
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on CV morbidity and mortality. The main data on zofenopril
efficacy come from the Survival of Myocardial Infarction
Long-Term Evaluation (SMILE) and SMILE-2, where
patients received this agent in addition to standard therapy.
In SMILE, 1556 patients with no history of congestive heart
failure and presenting <24 after onset of symptoms were
randomized to zofenopril 7.5–30 mg twice daily (bid). and
placebo. Incidence of death or severe congestive heart failure
at 6 weeks was significantly reduced by zofenopril compared
with placebo (7.1% vs 10.6%; p<0.05); the cumulative risk
reduction was 34% (p=0.018). The risk reduction with
zofenopril was 46% (p<0.018) for severe congestive heart
failure and 25% (p=0.19) for death (Figure 2). After 1 year,
the mortality rate was significantly lower in the zofenopril
group than in the placebo group (10% vs 14.1%) with a risk
reduction of 29% (p=0.011) (Figure 3) (Ambrosioni et al
1995). Similar results have been observed in a subgroup of
patients affected by type 2 diabetes (Borghi et al 2003).
In SMILE-2, 1024 thrombolyzed patients with acute MI
were randomized to receive oral zofenopril (30–60 mg/day)
or lisinopril (5–10 mg/day), starting within 12 hours of
completion of thrombolytic therapy and continuing for 42
days. The overall incidence of severe hypotension was
10.9% with zofenopril and 11.7% with lisinopril (p=0.38).
The incidence of drug-related severe hypotension was
slightly but significantly lower with zofenopril than with
lisinopril (6.7 vs 9.8%, p=0.048). The 6-week mortality rate
was 3.2% in the zofenopril group and 4.0% in the lisinopril
group (p=0.38), and no significant differences were
observed in the incidence of major cardiovascular
complications or any safety variables between the 2 ACE
inhibitors (Borghi and Ambrosioni 2003).
Moreover, the ischemic heart protective effect of
zofenopril has been clearly demonstrated in different animal
models (Frascarelli et al 2004; Evangelista and Manzini
2005; Leva et al 2006): the main proposed mechanisms of
action are interference with bradykinin metabolism,
preservation of protein sulfhydryl groups, and antioxidant
activity.
It has also been suggested (but yet not demonstrated in
humans) that the zofenopril–HCTZ combination may be
used to treat congestive heart failure. Preclinical data show
that, as with captopril, zofenopril significantly increases the
myocardial expression of collagen type III and normalized
the collagen type I/III ratio, thus preventing myocardial
hypertrophy in spontaneous hypertensive rats. The
hypertension related organ damage was more completely
prevented by zofenopril–HCTZ than by the enalapril–HCTZ
combination and it was related to an activation of endothelial
nitric oxide (NO) synthase expression and to a normalization
of the oxidative stress components due to angiotensin II
inhibition (Gagnon et al 2004).
Dietary sodium restriction (similar to that achievable
with HTCZ) increases the zofenopril-related attenuation of
Figure 2 Early efficacy of zofenopril treatment in patients with no history of congestive heart failure and presenting <24 h after onset of myocardial infarction
symptoms: results from the Survival of Myocardial Infarction Long-term Evaluation (SMILE) study.Vascular Health and Risk Management 2006:2(4) 346
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left ventricular dysfunction induced by myocardial
infarction (Westendorp et al 2004).
Preclinical data on combination therapy with zofenopril–
HCTZ indicated that, as well as preventing the development
of arterial hypertension, it provided more complete organ
protection than the combination of enalapril–HCTZ (García-
Estan et al 2006). This was demonstrated in a 8 week study
in hypertensive rats by a reduction in mortality, and
normalization of renal morphological and functional
alterations including improvements in excretory parameters.
Other preclinical data suggest that HCTZ could also
contribute to the cardiac and renal protective effect of
zofenopril by increasing the concentration of its
metabolite, zofenoprilat, in these target organs
(Westendorp et al 2005).
Interestingly, part of the organ-damage protection offered
by zofenopril may also be mediated by its antioxidant effect
and this has been clearly shown in both laboratory models
and in humans (Napoli et al 2004). For example, one clinical
study demonstrated that zofenopril, as with other sulfhidryl
compounds, was able to improve the oxidative balance in
hypertensive patients. This effect was accompanied by a
parallel increase in NO synthesis, counteracting the usual
inactivation of NO by O2 radical production and was not
observed with enalapril (Scribner et al 2003). Furthermore,
the negative effect of thiazides, of increasing free radical
levels through induction of the renin–angiotensin system,
could be counterbalanced by zofenopril’s antioxidant effect
in the combination.
Tolerability of Zofenopril–HCTZ
In controlled clinical trials involving approximately 600
patients, adverse events observed with the combination of
zofenopril–HCTZ were in line with those previously
reported with zofenopril or HCTZ monotherapy (Borghi et
al 2004). The most commonly reported adverse events were
dizziness, headache, and cough, as would be expected with
ACE inhibitor therapy. These adverse events were generally
mild-to-moderate in severity and were not correlated with
age or gender. Theoretically, the presence of the sulphydryl
group may be associated with an increased prevalence of
dysgeusia, but available clinical data do not support the
hypothesis that this side effect is more frequent with
zofenopril than with other drugs of the same class (Zanchetti
et al 2006).
In the dose-response study, a total of 9.9% of patients
reported an adverse event; 64.3% of these events were of
mild intensity (Parati et al 2005). In these patients 61.9% of
adverse events were determined to be treatment-related but
the majority of adverse events disappeared upon
discontinuation of treatment. The occurrence of treatment-
related adverse events was comparable among the treatment
groups, and the most common adverse events were cough
and polyuria. Treatment withdrawal occurred in only 1.7%
Figure 3 Relative risk reduction of overall mortality related to one year treatment with Zofenopril compared with placebo in the Survival of Myocardial Infarction
Long-term Evaluation (SMILE) study.Vascular Health and Risk Management 2006:2(4) 347
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of patients. There were no increases in low-density
lipoprotein cholesterol levels or triglycerides, blood glucose
or uric acid levels with combination therapy.
Importantly, in two studies zofenopril–HCTZ 30/
12.5 mg/day was at least as well tolerated as zofenopril
30 mg/day monotherapy with the combination having
therapy no detrimental effect on heart rate (Malacco and
Omboni 2005).
Finally, even though the available safety data are
encouraging, further clinical studies are needed to fully
confirm the long-term safety of the zofenopril–HCTZ
combination.
Place of Zofenopril–HCTZ in the
management of hypertension
Hypertension is the most commonly occurring independent
CV disease risk factor in the world (Kearney et al 2004).
One of the primary challenges for physicians in the
management of patients with hypertension is achieving
target BP levels in clinical practice. Physicians are now more
aware than ever before that optimal antihypertensive
treatment should be effective, ensure timely reductions in
BP levels, and be well tolerated to enhance patient
compliance.
The use of combination therapy in the treatment of
patients with hypertension is recommended by the ESH–
ESC, JNC-7 and the World Health Organization–
International Society of Hypertension (WHO-ISH) 2003
guidelines (ESH–ESC 2003; JNC-7 2003; WHO–ISH
2003). ESH–ESC and JNC-7 guidelines acknowledge that
the majority of patients will require two or more
antihypertensive agents to achieve target BP goals (ESH–
ESC 2003; JNC-7 2003). Therefore, in patients with
uncontrolled BP, physicians should consider initiating
combination therapy either with two separate agents or as a
fixed-dose combination. Combination therapy is also
justified in certain patient populations with hypertension
and co-morbidities (ie, diabetes, chronic kidney disease) for
whom rapid reduction of BP is required (ESH–ESC 2003;
JNC-7 2003).
The use of combination therapy as first-line treatment is
increasing as BP goals for antihypertensive therapy are
becoming more ambitious for all patients and, in particular,
for patients at a higher risk of CV complications. While
most guidelines (ESH–ESC 2003; JNC-7 2003) advocate
the combination of two agents from different classes as an
alternative to monotherapy, many physicians feel that this
does not allow the freedom to vary the dose of the individual
components according to patient response. It should be
emphasized that for fixed-dose combinations the individual
doses of each component have been selected on the basis of
careful investigation to determine the dose that provides
the greatest BP reductions with the lowest incidence of
adverse events in the largest proportion of patients (Zanchetti
1999).
The use of fixed-dose combination therapy with an ACE
inhibitor and a diuretic provides physicians with the means
to achieve BP control without the need for prolonged and
laborious dose-titrations necessary with initial monotherapy
(Gavras and Rosenthal 2004).
The results of a dose-response study comparing
zofenopril–HCTZ with each agent administered as
monotherapy clearly demonstrate that a greater
antihypertensive effect, in terms of the rate of patients with
normalized DBP, is achieved with combination therapy. In
addition, combined therapy provided sustained and
consistent BP control over the entire 24 h dosing interval.
These results suggest that the combination of zofenopril–
HCTZ may be indicated in patients who do not achieve target
BP on zofenopril 30 mg/day or up to 25 mg/day of HCTZ.
A well-designed study confirmed the greater BP lowering
efficacy of zofenopril–HCTZ 30/12.5 mg/day versus
zofenopril 30 mg/day monotherapy (Borghi et al 2004). The
advantage of zofenopril–HCTZ combination therapy in
normalizing BP was particularly evident in patients who
were non-responsive to monotherapy (Malacco and Omboni
2005).
The overall tolerability profile of zofenopril–HCTZ is
consistent with the profile of each individual agent. A direct
comparison of zofenopril–HCTZ with each agent
administered as monotherapy did not show any significant
differences in the nature, severity or incidence of treatment-
related adverse events (Malacco and Omboni 2005; Parati
et al 2005). Headache, dizziness, cough and polyuria were
the most frequently reported treatment-related adverse
events. Neither patient gender nor age had any effect on the
tolerability of the zofenopril–HCTZ combination. Notably,
fewer patients discontinued treatment with combination
therapy due to adverse events (Zanchetti et al 2006).
The fixed combination of zofenopril–HCTZ is expected
to demonstrate potential additive cardiovascular protective
properties as suggested by the efficacy of zofenopril
monotherapy in reducing the incidence of death or severe
congestive heart failure post myocardial infarction in the
SMILE study (Ambrosioni et al 1995). Preclinical dataVascular Health and Risk Management 2006:2(4) 348
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support its efficacy in providing cardiovascular and renal
end-organ protection (Borghi et al 2004).
Nevertheless, as for all fixed-combination treatment
there are also some potential disadvantages: firstly, the
difficulty in modifying the dosage of any of the individual
drug components according to BP response; secondly, the
difficulty in distinguishing the causative agent in any cases
of atypical side effects; and finally, the administration of
two drugs may also increase the risk of pharmacological
interaction with other agents given concomitantly.
Conclusion
In conclusion, data from clinical trials with zofenopril–
HCTZ indicate that this combination provides optimal BP
control in a larger proportion of patients compared with
monotherapy, whilst maintaining the tolerability profile
observed with each individual component and thereby
enhancing patient compliance. The efficacy and safety
profile of zofenopril–HCTZ highlights that this combination
is a useful addition to currently available therapy for patients
with BP inadequately controlled by monotherapy, as well
as for patients who require more rapid and intensive BP
control. Further long-term large randomized clinical trials
are needed to establish that the zofenopril–HCTZ
combination has the same cardiovascular and renal
protective effects demonstrated by other ACE inhibitors.
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